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Background: The prevalence of asymptomatic bacteriuria (ASB) in pregnancy is 2-10% and is associated with both
maternal and neonatal adverse outcomes as pyelonephritis and preterm delivery. Antibiotic treatment is reported
to decrease these adverse outcomes although the existing evidence is of poor quality.
Methods/Design: We plan a combined screen and treat study in women with a singleton pregnancy. We will
screen women between 16 and 22 weeks of gestation for ASB using the urine dipslide technique. The dipslide is
considered positive when colony concentration ≥105 colony forming units (CFU)/mL of a single microorganism or
two different colonies but one ≥105 CFU/mL is found, or when Group B Streptococcus bacteriuria is found in any
colony concentration. Women with a positive dipslide will be randomly allocated to receive nitrofurantoin or
placebo 100 mg twice a day for 5 consecutive days (double blind). Primary outcomes of this trial are maternal
pyelonephritis and/or preterm delivery before 34 weeks. Secondary outcomes are neonatal and maternal morbidity,
neonatal weight, time to delivery, preterm delivery rate before 32 and 37 weeks, days of admission in neonatal
intensive care unit, maternal admission days and costs.
Discussion: This trial will provide evidence for the benefit and cost-effectiveness of dipslide screening for ASB
among low risk women at 16–22 weeks of pregnancy and subsequent nitrofurantoin treatment.
Trial registration: Dutch trial registry: NTR-3068Background
Asymptomatic bacteriuria (ASB) is the presence of sig-
nificant bacteriuria without the symptoms of a urinary
tract infection (UTI). ASB occurs in 2-10% of pregnant
women [1]. ASB during pregnancy can lead to serious
complications for both mother and child. The incidence
of ASB is similar in both pregnant and non-pregnant
women [2]. Pregnant women with ASB, however, de-
velop pyelonephritis more often, probably due to the
anatomic and physiologic changes that occur during
pregnancy, which may facilitate bacterial growth and* Correspondence: b.m.kazemier@amc.uva.nl
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reproduction in any medium, provided the orascending of bacteria to the kidneys [3]. If left untreated,
20% to 40% of pregnant women with ASB will develop
pyelonephritis [2,4,5].
Other possible adverse effects, such as preterm deliv-
ery and delivering a low birth weight infant are less well
established. Preterm delivery is the main cause of neo-
natal mortality and morbidity worldwide. The causal
mechanisms remain unknown. One of the hypotheses is
that endotoxins released by bacteria cause uterine con-
tractions leading to preterm delivery.Necessity of screening for ASB
Some national guidelines [1,6,7] recommend ASB screen-
ing and treatment in pregnancy. However, these guidelines
are based on research conducted more than 30 year ago.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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causing mechanisms of pyelonephritis has developed.
Since the methods used in these early studies are inad-
equately described, interpretation of this evidence is diffi-
cult and the conclusions that can be drawn are limited.
Although many articles have been published on ASB in
pregnancy, the role of ASB in perinatal outcomes is not
clear [8]. Another problem is that most recent papers
focus on the best treatment strategies instead of evaluating
the actual need for a screen and treat program.
The widespread use of antibiotics as a consequence of
the screening programs is reason for concern. The OR-
ACLE Children Study II [9] showed increased functional
impairment in children from mothers using antibiotics for
the prevention of preterm labour in pregnancy. Other
studies also showed an adverse effect of antibiotics on the
offspring, such as increased antibiotic resistance in late-
onset serious bacterial infections [10];[11]. Considering
these results, one should carefully balance the conse-
quences of bacteriuria in pregnancy against the possible
effects of antibiotics, before routinely treating all women
with ASB.
Antibiotics choice and duration
There is no consensus in the literature on either the dur-
ation of therapy or the choice of antibiotic. As a result
practice is guided by national or local practices and re-
sistance patterns[8]. A recent Cochrane review on the
treatment duration for ASB underlines this lack of clear
evidence on the best treatment[12].
The latest guidelines of the Infectious Disease Society
of America (IDSA), published in 2005, recommend for
the treatment of ASB a 3 to 7-day course for the treat-
ment of ASB that includes sulphonamides, nitrofuran-
toin, nalidíxic acid, amoxicillin or trimethoprim [1].
E coli is the most common pathogen found in ASB [3]
and treatment should be targeted to the most common
pathogens. Nitrofurantoin has proven to be safe in preg-
nancy [13,14] with very low resistance levels in Nether-
lands [15]. Nitrofurantoin is first choice in the treatment
of cystitis in pregnancy in the Netherlands [16,17].
The Dutch guidelines of the Dutch Society of Obste-
trics and Gynaecology (NVOG ) and the Dutch General
Practitioners Society (NHG) do not currently recom-
mend routine screening and treatment of ASB in preg-
nancy[16,17] because convincing evidence is lacking.
The Netherlands is one of the few countries which can
still properly investigate this important question because
a non treating policy of woman with ASB does not vio-
late the guideline.
In view of the lack of good clinical evidence on the
subject and the resulting practice variation, we think
that an appropriately designed clinical trial evaluating
the costs and effects of a screen and treat program isurgently needed. In a national cohort study women will
be screened for ASB with the dipslide technique.
Women with ASB will be randomised to either placebo
or nitrofurantoin.
Methods/design
Outline
The study will be a prospective cohort screening study
with a randomised clinical trial embedded. We will
screen a large cohort of women with low risk singleton
pregnancies at 16–22 weeks gestation with the dipslide
technique. Women with a positive dipslide without
symptoms of a UTI will be randomly allocated to receive
either nitrofurantoin or placebo for 5 days. To mask
women for their bacteriuria status a small sample of
women without ASB will also be offered the possibility
to participate in the study. Women without ASB will al-
ways receive placebo. Both women and researchers will
be unaware of the bacteriuria status and treatment allo-
cation. Because of the blinding of bacteriuria status,
women with GBS bacteriuria will not receive intrapar-
tum antibiotics in the absence of other risk factors.
The objective of the randomized trial is to evaluate
whether nitrofurantoin treatment of women with ASB is
effective in reducing the risk of preterm delivery and/or
pyelonephritis (primary outcome) and adverse neonatal
outcome (secondary outcome).
Participants/eligibility criteria
The study is set in the Dutch Obstetric Consortium, a
collaboration of obstetric practices in the Netherlands. A
variety of clinics, including university hospitals, teaching
hospitals, non-teaching hospitals, ultrasound centres and
midwifery practices will participate in this trial. Women
with a singleton pregnancy without symptoms of a urin-
ary tract infection at 16–22 weeks of gestation can par-
ticipate in the ASB screening study.
Women with a history of spontaneous preterm deliv-
ery before 34 weeks, signs of threatening preterm deliv-
ery, foetal congenital malformations, use of antibiotics at
time of screening, known G6PD deficiency or allergy to
nitrofurantoin or risk factors for complicated UTI (dia-
betes mellitus, immunosuppressive medication, func-
tional or structural abnormalities of the urinary tract)
are excluded from the screening study.
Procedures, recruitment, randomisation and collection of
baseline data
ASB screening trial
In the ASB screening trial, we will offer low risk women
with a singleton pregnancy the possibility to be screened
for ASB with the dipslide technique. At the 16th week of
gestation the timing of screening is considered optimal
[4,18]. For logistic reasons we decided to do the screening
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abnormalities is performed in the Netherlands.
A single dipslide (UricultW, Orion Diagnostica) con-
sisting of two different media (green cysteine lactose
electrolyte deficient medium and reddish MacConkey
medium) will be used to diagnose ASB. Previous re-
search showed that the dipslide is a promising alterna-
tive for the conventional culture, which is currently
considered the gold standard[19,20];[3]. The dipslide has
98.0% sensitivity and 99.6% specificity for detecting ASB
in pregnancy [21]. Urinary culture is not feasible in the
Dutch antenatal care system since 70% of Dutch women
attend antenatal care at a midwifery practice. Hence,
there is no direct access to a microbiology laboratory to
perform the cultures.
The dipslide will be inoculated with midstream urine
at a hospital, ultrasound centre or midwifery practice.
Perineal cleansing prior to voiding is not necessary since
it does not decrease bacterial contamination [22]. The
dipslides will be sent by mail to the laboratory for infec-
tious diseases in Groningen, the Netherlands the same
day. Laboratory technicians will read the dipslide directly
when incubated for 2 to 3 days at room temperature. If
no colonies have been formed, the dipslide will be incu-
bated for another 24 hours at 35o Celsius.
Dipslides are considered positive when the colony con-
centration is ≥ 105 CFU/mL of a single microorganism or
when two different colonies are present but one has a
concentration of ≥105 CFU/mL. When Group B Strepto-
coccus (GBS) is found also colony concentrations
<105 CFU/mL are considered positive because treat-
ment may still be beneficial [23]. When more species are
present the dipslide is considered contaminated.
All women participating in the ASB screening study
will receive two questionnaires. The first questionnaire
contains questions about ethnicity, marital status, length,
weight, education, smoking, alcohol- and drug use, co
morbidity, parity, inter-pregnancy interval and exclusion
criteria. This questionnaire will be filled out at the mo-
ment of screening. The second questionnaire will be sent
to the participants 6 weeks after their due date. It con-
tains questions about UTIs, use of antibiotics and hos-
pital admissions during this pregnancy, pregnancy
complications and pregnancy outcomes. Furthermore we
will ask all women in the screening study for informed
consent to collect data on their pregnancy outcomes.
ASB treatment trial
Women eligible for the ASB treatment trial will be iden-
tified by the laboratory personnel participating in this
study. A research midwife or -nurse will contact these
women for participation in the treatment trial.
Before entering the study, women will be informed
about the aims, methods, reasonably anticipated benefitsand potential hazards of the study. Participation is vol-
untary and withdrawal of consent to participate is pos-
sible at any time during the study. After giving sufficient
information, written informed consent will be asked for.
Women eligible for the ASB treatment trial who do not
give informed consent, will be registered. Nitrofurantoin
will not be offered to these women.
After participant data have been entered in a web based
database, computerized randomisation will take place. The
women with ASB will be randomised 1:1 for nitrofuran-
toin and placebo. Women without ASB (used for blinding
of bacteriuria status) will always receive placebo.
Intervention
Each study participant will be given a jar labelled “ASB
treat study” which contain either 100 mg capsules of
nitrofurantoin (Nitrofurantoin MC, TioFarma, the Neth-
erlands) or identical-appearing capsules of placebo (Tio-
Farma, the Netherlands).
The oral study medication will be self-administered
twice a day for 5 consecutive days. The label codes indi-
cating nitrofurantoin or placebo are blinded for the par-
ticipants and researchers. The deblinding list is present
in the central pharmacy. For emergency cases, a closed
envelope with the label codes is also available at the
study centre. The data will be disclosed to the research-
ers in case of emergencies and otherwise after collection
and analysis of the primary outcomes. Researchers
involved in the follow up program of the offspring of
women participating in this study will remain blinded
for a longer period. For purpose of the interim analysis
the label codes will become available to the epidemiolo-
gist involved in the study as A and B.
All participants who receive study medication -i.e. the
screen positives as well as the random subsample of
screen negatives-, will have follow up dipslides done
1 week after the end of treatment. Participants with a
persistent positive culture and a subsample of partici-
pants with a negative culture will receive again (blinded)
study medication. The participants who received nitro-
furantoin will again receive nitrofurantoin, placebo parti-
cipants will again receive placebo. One week after this
second intervention, once again a dipslide is performed.
Outcome measures
The primary outcomes for the screen and treat study are
the development of pyelonephritis and delivery before
34 weeks. Pyelonephritis is defined as an episode of fever
(≥38.0°C), symptoms (nausea, vomiting, chills, costo-
vertebral tenderness) and a positive urine culture. The
primary outcome measure will be recorded 6 weeks after
the expected due date.
Secondary outcome is an adverse neonatal outcome
(death or severe morbidity). The composite morbidity
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distress syndrome (RDS), bronchopulmonary dysplasia
(BPD), periventricular leucomalacia > grade 1, intracer-
ebral haemorrhage > grade II, necrotizing enterocolitis
(NEC) > stage 1, proven sepsis (including GBS sepsis)
and death before discharge from the nursery.
Other outcome parameters are: neonatal weight, time
to delivery, preterm birth rate before 32 and 37 weeks,
days of admission in neonatal intensive care unit, mater-
nal morbidity (including UTI), chorioamnionitis, mater-
nal admission days for (threatened) preterm labour and/
or pyelonephritis and costs.
Furthermore, we will look at growth, physical condi-
tion and neurodevelopmental outcome of the child at
24 months (corrected) age.
Apart from clinical outcome, the cost-effectiveness of
screening for ASB (as done in ASB screening), and sub-
sequent treatment in cases of ASB (as done in ASB
treatment trial), will be assessed.
Follow up of women and infants
We plan follow-up of infants at the corrected age of
24 months with the Ages & Stages Questionnaires (ASQ)
and the Child Behavioural Checklist (CBCL). The check-
lists will be sent to the parents of the child. In case the
parents do not return the questionnaire, a reminder will
be sent. We will also ask them to report length, weight
medical history and medical consumption of the child.
Data analysis
The results of the screen cohort will allow us to describe
the incidence of ASB in the Netherlands as well as to ex-
plore risk factors for developing ASB or pyelonephritis.
The results of the randomised clinical trial will be ana-
lyzed according to the intention to treat principle. The
effectiveness of nitrofurantoin versus placebo will be
assessed by calculating relative risks and 95% confidence
intervals. The number of primary- and secondary out-
comes will be compared between the ASB positive and
ASB negative (ASB screen study) and treatment and
control (ASB treat study) groups.
Interim analysis
Interim analysis will be monitored by an independent
Data Safety Monitoring Committee. We plan an interim
analysis for futility and safety after 100 participants in
the ASB treat study. This analysis will be done by an in-
dependent person who will be unaware of the allocation
of treatment when data are judged for effectiveness.
Statistical issues
Sample size calculation
Among women positive for ASB, we anticipate the oc-
currence of the primary outcome (delivery before34 weeks and/or pyelonephritis) to be 10% in the treat-
ment group and 25% in the no treatment group. If ASB
is not treated, 20% of pregnancies with ASB will be com-
plicated by pyelonephritis compared to 2% of pregnan-
cies without ASB [24]. Treatment of ASB results in a
decrease of pyelonephritis compared to women who
were not treated. Using a two-sided test with an alpha
0.05 and a beta of 0.8, 220 women with ASB (110 per
arm) are needed in the study. Anticipating a 5% inci-
dence of ASB, we need to screen 4.400 women. Obvi-
ously, final recruitment statistics will depend on the
screen positive rate, which is one of the study questions.
From our previous experience in the Triple P trial [25]
we learned that Dutch women are very reserved in tak-
ing study medication for asymptomatic conditions in
pregnancy. If during this trial it becomes clear that very
few women consent to participate in the ASB treat study
we will not increase our screening cohort indefinitely to
reach our planned randomisations.
Economic evaluation
General considerations
The economic analysis will be performed from a societal
perspective. Both costs and outcomes will be discounted
with a discount rate of 5%. The economic analysis of the
trial itself is not of interest. If nitrofurantoin is found to
decrease the probability of pyelonephritis or preterm de-
livery, then the savings due to decreased maternal and
neonatal admission will always outweigh the costs of
nitrofurantoin, which are negligible. The true economic
question to be answered, when the treatment trial shows
a beneficial effect, is whether the costs of screening
(number needed to screen to detect one woman with
ASB) outweigh the cost reduction and health benefits
from treatment with nitrofurantoin.
Cost analysis
The study design will enable us to compare the costs
and effects of the following strategies:
I. no screening for ASB
II. screening for ASB and treatment of women with ASB
For each of these strategies, we will calculate the costs
as well as the effects in terms of pyelonephritis or pre-
term delivery. In the cost-effectiveness analysis, we will
then calculate the costs per prevented case of pyeloneph-
ritis or preterm delivery. Thus, the cost-effectiveness
analysis will assess the balance between number needed
to treat and number needed to screen.
Data safety monitoring committee
Serious Adverse Events (SAEs) and Suspected Unexpected
Serious Adverse Reactions (SUSARs) will be reported to a
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can order to perform an extra interim analysis and, if indi-
cated, terminate the trial prematurely.
Ethical considerations
This study is approved by the National Central Commit-
tee on Research involving Human Subjects (CCMO -
NL35375.018.11) and by the ethics committee of the
Academic medical centre Amsterdam (ref. no MEC
2011_073).
Discussion
To our knowledge there are no other ongoing trials in
the Netherlands or other countries, evaluating a screen
and treat strategy for ASB with the dipslide technique
(http://www.controlled-trials.com/mrCT/). This trial will
provide evidence for the usefulness and cost-effectiveness
of screening for ASB at 16–22 weeks of pregnancy with a
dipslide and subsequent nitrofurantoin treatment among
low risk women.
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